According to IMS Health forecasts, the global generics market is expected to grow at 20% to reach a huge $80 billion by 2008. Generics is the future for drugs, and US is the future for generics. Current low profit margins are simply temporary structural adjustments and would necessarily disappear in the long run as huge supply demand gaps would encourage price increases for all players. Though Ranbaxy should surely look at diversifying its portfolio at other overseas markets too, the current setback should not tempt Ranbaxy to limit its operations and marketing exposure in the most lucrative market of the world.
For Detail IIPM Editorial Article, Click here
Source: IIPM Editorial, 2006
